On Tuesday, Merck & Co (NYSE:MRK) Inc. emerged victorious in a significant legal dispute concerning its Gardasil vaccine, which is designed to prevent cervical and other serious cancers. U.S. District ...

if extracted with benzene at a suitable pH, pass into the benzene medium, very often with a change of colour. This communication reports our preliminary results with methylene blue.

A federal judge in North Carolina on Tuesday granted an order for summary judgment in favor of Merck (NYSE:MRK) regarding lawsuits accusing the drugmaker of failing to warn consumers its Gardasil ...

Merck has opened a $1 billion, 225,000-square-foot facility at its Durham campus dedicated to vaccine manufacturing, the drug giant announced Tuesday. Merck has opened a $1 billion, 225,000-square ...

Opening highlights effort to expand U.S. manufacturing through a $1 billion investment DURHAM, N.C., March 11, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States ...

We recently compiled a list of the 11 Oversold Blue Chip Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against ...

Rember® is a purified, proprietary formulation of methylthioninium chloride (MTC), also known as methylene blue. This old drug predates the FDA. It is being widely used in Africa to treat malaria, as ...

Learn about our editorial policies The Relative Strength Index (RSI) is one of the most widely used momentum indicators in technical analysis. It helps traders identify overbought and oversold ...

A dispute over a microscopic enzyme is threatening Merck & Co. plans to sell a new version of Keytruda, the cancer drug that generates nearly half of the company’s sales. Merck has been tweaking ...

The chemical compound known as methylene blue boasts a long history of use in numerous medical settings. Its importance is primarily drawn from its ability to enhance mitochondrial function.

You may have access to this article through your institution. Your institution does not have access to this content. Add or change your institution or let them know you’d like them to include access.

On February 4, Merck released financial results for Q4 2024, which, as in previous quarters, once again beat analysts' expectations. This was driven by a strong performance by its oncology ...